YOLFTbeta
DBV Technologies

DBV Technologies

0QAJ · LSE

1.98EUR-0.14 (-6.55%)

Price History

Full chart

Market Stats

Previous Close2.11
Open1.98
Day Range1.75 – 1.98
52-Week Range1.99 – 4.46
Volume0
Market Cap147.76M
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta-0.23
50-Day Avg3.20
200-Day Avg3.15

About

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Company Details

Leadership

  • Mr. Daniel TasséCEO & Director · b. 1960
  • Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A.Chief Financial Officer · b. 1969
  • Dr. Pharis Mohideen M.D.Chief Medical Officer · b. 1965
  • Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C.Chief Operations Officer
  • Mr. Jonathan NeelyVP & Head of Investor Relations
  • Ms. Michele F. RobertsonChief Legal Officer
  • Mr. James BriggsChief Human Resources Officer · b. 1972
  • Mr. Kevin TrappChief Commercial Officer · b. 1967
  • Alan KerrSenior VP & Head of Global Regulatory Affairs
  • Mr. Pascal WotlingChief External Manufacturing & Supply Chain Officer

Financials

Income Statement

Currency: EUR2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-31
Total Revenue10.26M13.46M16.43M14.71M11.28M--
Growth (%)-+31.10%+22.07%-10.46%-23.33%--
Cost of Revenue1.28M1.81M1.78M----
Gross Profit8.98M11.65M14.64M----
Gross Margin87.49%86.57%89.16%----
Operating Expense140.08M175.47M202.44M----
Operating Income-131.10M-163.82M-187.79M-171.02M-158.84M--
Operating Margin-1277.31%-1217.42%-1143.30%-1162.79%-1408.67%--
Net Income-129.41M-166.88M-187.65M-172.01M-159.56M--
Net Income Margin-1260.80%-1240.18%-1142.44%-1169.51%-1415.01%--
Interest Expense000000-
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%--

Balance Sheet

Currency: EUR2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-31
Total Assets324.85M200.91M194.06M271.73M272.25M--
Total Liabilities50.45M54.10M57.02M78.54M66.75M--
Total Equity274.40M146.80M137.04M193.19M205.49M--
Cash124.40M119.57M51.45M135.37M154.01M--

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Operating Cash Flow-67.27M-129.16M-136.62M-148.35M-165.61M-108.24M-55.67M--
Investing Cash Flow-9.38M-8.85M-8.64M-5.66M-2.87M-433.00K-100.00K--
Financing Cash Flow1.88M323.15K130.68M207.58M149.55M274.00K194.12M--
Capital Expenditure9.27M8.53M4.71M5.57M2.79M910.00K754.00K00

Earnings

Report DateJun 30, 2015Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Mar 7, 2024May 9, 2024Jul 30, 2024Sep 30, 2024Mar 24, 2025Mar 31, 2025Jul 30, 2025Oct 31, 2025Mar 26, 2026Apr 30, 2026Jul 29, 2026Oct 28, 2026
EPS Estimate-------------------0.29-0.21-0.09-0.06-0.08-0.08
EPS Actual-0.43-0.45-0.46-0.37-0.22-0.27-0.33-0.18-0.41-0.20-0.24-0.16-0.11-0.26-0.32-0.29-0.22-0.25-0.27-0.21-0.20-0.10-0.10-
Surprise------------------5.34%1.24%-123.44%-58.33%-25.00%-
Timing------------After-hoursAfter-hoursAfter-hours-Pre-market-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap147.76M
Enterprise Value452.45M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.00
Book Value0.4779
Revenue (TTM)5.04M
Gross Profit (TTM)5.04M
EBITDA-174.76M
Profit Margin0.00%
Operating Margin-7228.57%
Return on Equity-142.68%
Return on Assets-60.61%
Shares Outstanding0
Shares Float174.70M
Beta-0.23
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%